Galmed Pharmaceuticals (NASDAQ:GLMD) Earning Somewhat Positive Media Coverage, Analysis Finds
News stories about Galmed Pharmaceuticals (NASDAQ:GLMD) have been trending somewhat positive on Monday, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Galmed Pharmaceuticals earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.4127957772202 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of analysts have issued reports on GLMD shares. Maxim Group set a $9.00 price objective on Galmed Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 15th. ValuEngine upgraded Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 17th. HC Wainwright boosted their price objective on Galmed Pharmaceuticals from $12.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, August 8th. Finally, Zacks Investment Research upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price objective for the company in a report on Wednesday, August 2nd.
Shares of Galmed Pharmaceuticals (GLMD) traded down 0.98% on Monday, reaching $8.10. The company had a trading volume of 18,667 shares. Galmed Pharmaceuticals has a 52 week low of $2.78 and a 52 week high of $8.60. The company’s market capitalization is $98.97 million. The company has a 50 day moving average of $6.96 and a 200-day moving average of $5.39.
Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its earnings results on Monday, July 31st. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.11. The business had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.29 million. Galmed Pharmaceuticals had a negative return on equity of 141.13% and a negative net margin of 1,443.98%. Analysts predict that Galmed Pharmaceuticals will post ($0.94) earnings per share for the current fiscal year.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.